{
    "nctId": "NCT02199418",
    "briefTitle": "Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer",
    "officialTitle": "Phase 2 Study of Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Locally Advanced Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 132,
    "primaryOutcomeMeasure": "Pathological complete response of breast and lymph nodes",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women aged \u226518years and \u226470 years\n2. At least on measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size \u22652 cm, T2-4 N0-2M0\n3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as \\>1% stained cells and HER2-positive is defined as immuno-histochemistry (IHC) 3+ or FISH ratio \u2265 2.0\n4. No prior systemic or loco-regional treatment of breast cancer\n5. ECOG 0-2\n6. Adequate bone marrow function:WBC\u22654.0\u00d7109/L, Absolute neutrophil count\uff08ANC\uff09\u22651.5\u00d7109/L, Platelets\uff08PLT\uff09\u2265100\u00d7109/L, Hemoglobin\uff08Hb\uff09\u226590g/L;aspartate aminotransferase(AST),Alanine aminotransferase (ALT)\u22641.5 upper normal limit \uff08UNL\uff09, creatinine\u22641.5 UNL, bilirubin\u22641.5UNL\n7. No obvious main organs dysfunction\n\nExclusion Criteria:\n\n1. Unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug\n2. Patient is pregnant or breast feeding\n3. Inflammatory breast cancer and metastatic breast cancer\n4. Any evidence of sense or motor nerve disorders\n5. Patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection\n6. Any concurrent malignancy other than breast cancer\n7. Know severe hypersensitivity to any drugs in this study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}